BC Innovations | Sep 19, 2019
Product Development

Anokion puts liver to the test

Data presented Sept. 13 at a major multiple sclerosis meeting showcased the ability of Anokion’s liver targeting technology to induce immune tolerance. Armed with a fresh $40 million series B round, Anokion S.A. is developing...
BC Innovations | Mar 26, 2019
Distillery Therapeutics

The short-chain fatty acid pentanoate for MS

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis Cell culture and mouse studies suggest the short-chain fatty acid pentanoate could help treat MS. In primary mouse T helper type 17 (Th17) cells pentanoate increased expression of...
BC Innovations | Jan 25, 2019
Product R&D

Rubius turns immunotherapy red

As it gets ready to bring the first engineered red blood cell therapy into the clinic, Rubius Therapeutics Inc. is working up the next generation of RBC therapies to mimic immune cell interactions. The company...
BC Innovations | Dec 11, 2018
Translation in Brief

Diseased oligodendrocytes

A Karolinska Institute team has identified subsets of oligodendrocyte lineage cells that may trigger T cell immunity in multiple sclerosis and proposed the cells as new disease targets. The findings suggest the myelin-producing cells are...
BC Innovations | Jul 25, 2017
Distillery Techniques

Drug platforms

TECHNOLOGY: Fusion proteins Fusion proteins consisting of an engineered IgG1 fragment and antigens could be used to clear disease-associated or imaging antibodies from circulation. The fusion protein consists of two parts: an IgG1 Fc fragment...
BC Innovations | May 31, 2017
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest promoting ERDR1 expression could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, overexpression of ERDR1 in T cells decreased the number of MOG...
BC Innovations | Apr 11, 2017
Distillery Therapeutics

Autoimmune disease; endocrine / metabolic

INDICATION: Multiple sclerosis (MS); diabetes Mouse studies suggest red blood cells decorated with disease-associated autoantigens could help treat MS, Type I diabetes and other autoimmune diseases. Disease-associated peptides were covalently attached to the surfaces of...
BC Innovations | Mar 31, 2016
Distillery Therapeutics

Therapeutics: Sialic acid; myelin oligodendrocyte glycoprotein (MOG)

Autoimmune disease INDICATION: Autoimmune; multiple sclerosis (MS) Cell culture and mouse studies suggest sialic acid-antigen conjugates could help treat MS and other autoimmune diseases. In splenic and bone marrow-derived dendritic cells (DCs) co-cultured with T...
BC Innovations | Mar 10, 2016
Distillery Therapeutics

Therapeutics: Major histocompatibility complex class II (MHCII); glucose-6-phosphatase catalytic 2 (G6PC2; IGRP); proteolipid protein 1 (PLP1); myelin oligodend

Autoimmune disease INDICATION: Diabetes; rheumatoid arthritis (RA); multiple sclerosis (MS) Mouse studies suggest nanoparticles coated with MHCII molecules bound to disease-relevant peptides could help treat Type I diabetes, RA and MS. In a mouse model...
BioCentury | Jun 9, 2014
Emerging Company Profile

Anokion: Developing tolerance

Anokion S.A. is using its antigen-specific tolerance platform to develop less immunogenic versions of existing drugs. In the longer term, the company wants to use the technology to develop novel autoimmune therapeutics. For existing protein...
Items per page:
1 - 10 of 35